AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca PLC (NASDAQ:AZN) saw its American Depositary Receipts (ADRs) increase by 2.2% following a report from The Times suggesting that CEO Sir Pascal Soriot has privately shown interest in ...

Sky's James Sillars writes that a government, struggling for authority and prioritising economic growth, can not afford to allow the FTSE 100's biggest company to leave London in favour of New York.

AstraZeneca’s chief executive has discussed shifting the company’s stock market listing to the US in a move that would deal a huge blow to London.

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – and potentially even its domicile – according to an unconfirmed media ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...

--AstraZeneca's chief executive is considering moving its listing from London to the U.S. due to U.K. restrictions on medicines and pricing, The Times reports, citing unnamed sources. --Pascal ...

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times reported on Tuesday, citing multiple sources. Soriot has privately expressed a ...

(Reuters) -AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing ...